Latest Hospitality News

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

HeraMED has inked a 12-month commercial agreement with Philips’ U.S. subsidiary to deliver an integrated digital maternity care platform to American hospitals, combining cutting-edge monitoring devices with HeraMED’s remote patient monitoring technology.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

SRG Global has landed $650 million worth of contracts spanning water, defence, energy, and more across Australia and New Zealand, reinforcing its position as a diversified infrastructure leader.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed three new cloud-based contracts worth a combined minimum of A$29 million, reinforcing its strong foothold across diverse healthcare segments.

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Monash IVF Group reported solid FY25 revenue and EBITDA growth despite sector softness and clinical incidents, while announcing a leadership transition and dividend pause.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

Orthocell Limited reports growing adoption of its Remplir™ nerve repair product in nerve-sparing prostate cancer surgeries across Australia, positioning for a significant U.S. market expansion. The company is investing in research and commercial infrastructure ahead of a medium-term U.S. launch.